These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 9666879

  • 1. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease.
    Di Somma C, Colao A, Pivonello R, Klain M, Faggiano A, Tripodi FS, Merola B, Salvatore M, Lombardi G.
    Clin Endocrinol (Oxf); 1998 May; 48(5):655-62. PubMed ID: 9666879
    [Abstract] [Full Text] [Related]

  • 2. Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus.
    Pivonello R, Faggiano A, Di Somma C, Klain M, Filippella M, Salvatore M, Lombardi G, Colao A.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2349-52. PubMed ID: 10404801
    [Abstract] [Full Text] [Related]

  • 3. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
    Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
    [Abstract] [Full Text] [Related]

  • 4. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study.
    Di Somma C, Pivonello R, Loche S, Faggiano A, Klain M, Salvatore M, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2003 Mar; 58(3):302-8. PubMed ID: 12608935
    [Abstract] [Full Text] [Related]

  • 5. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 6. Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease.
    Di Somma C, Pivonello R, Loche S, Faggiano A, Marzullo P, Di Sarno A, Klain M, Salvatore M, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2002 Feb; 56(2):153-8. PubMed ID: 11874405
    [Abstract] [Full Text] [Related]

  • 7. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 8. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
    Ravn P, Clemmesen B, Christiansen C.
    Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
    [Abstract] [Full Text] [Related]

  • 9. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
    Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G, Pivonello R, Panza N, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732
    [Abstract] [Full Text] [Related]

  • 10. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS.
    Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
    [Abstract] [Full Text] [Related]

  • 11. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome.
    Minetto M, Reimondo G, Osella G, Ventura M, Angeli A, Terzolo M.
    Osteoporos Int; 2004 Nov; 15(11):855-61. PubMed ID: 15034643
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
    Christopoulou GE, Stavropoulou A, Anastassopoulos G, Panteliou SD, Papadaki E, Karamanos NK, Panagiotopoulos E.
    J Pharm Biomed Anal; 2006 Jun 07; 41(3):891-7. PubMed ID: 16488571
    [Abstract] [Full Text] [Related]

  • 13. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
    Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, Corstens FH, Kloppenborg PW.
    J Clin Endocrinol Metab; 1995 Oct 07; 80(10):2859-65. PubMed ID: 7559865
    [Abstract] [Full Text] [Related]

  • 14. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    J Bone Miner Metab; 2005 Oct 07; 23(3):238-42. PubMed ID: 15838627
    [Abstract] [Full Text] [Related]

  • 15. Quantitative ultrasound of bone and markers of bone turnover in Cushing's syndrome.
    Cortet B, Cortet C, Blanckaert F, d'Herbomez M, Marchandise X, Wémeau J-L, Decoulx M, Dewailly D.
    Osteoporos Int; 2001 Oct 07; 12(2):117-23. PubMed ID: 11303711
    [Abstract] [Full Text] [Related]

  • 16. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, Algra A, Buskens E, Hofbauer LC, Oostveen AC, Bruyn GA, Dijkmans BA, Bijlsma JW.
    J Rheumatol; 2007 May 07; 34(5):1051-7. PubMed ID: 17407214
    [Abstract] [Full Text] [Related]

  • 17. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Yonsei Med J; 2005 Dec 31; 46(6):750-8. PubMed ID: 16385649
    [Abstract] [Full Text] [Related]

  • 18. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment.
    Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S.
    Calcif Tissue Int; 1998 Aug 31; 63(2):102-6. PubMed ID: 9685512
    [Abstract] [Full Text] [Related]

  • 19. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006 Aug 31; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 20. Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women.
    Tseng LN, Sheu WH, Ho ES, Lan HH, Hu CC, Kao CH.
    Metabolism; 2006 Jun 31; 55(6):741-7. PubMed ID: 16713432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.